Pfizer jumps into the heated PhIII race for new-wave JAK inhibitors — but safety frets loom large
Pfizer has racked up a positive slate of Phase III data for its anti-inflammatory JAK1 inhibitor abrocitinib (PF-04965842), which the pharma giant is hoping to steer to the FDA relatively soon as it looks to get into a heated blockbuster race that’s been heavily overshadowed by new safety warnings for the class.
All we’re getting now are some unspecified — though promising — results, with the pharma giant laying claim to a statistically significant result against a placebo for atopic dermatitis. Pfizer, though, wants to go up against some deeply entrenched rivals in a highly competitive field, and there’s no real insight to offer on how that stacks up.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
